Login to Your Account



Earnings Roundup


Thursday, May 3, 2012
• AMAG Pharmaceuticals Inc., of Lexington, Mass., reported first-quarter revenues of $15.5 million, including $13.6 million in net revenues from Feraheme (ferumoxytol) injection in iron deficiency anemia (IDA). Net Feraheme product revenues for the first quarter were $13.6 million, compared to $10.9 million in the first quarter of 2011. Provider demand for the intravenous drug during the first quarter was approximately 26,600 grams, representing a 30 percent increase over the first quarter of 2011 and a 10 percent increase over the fourth quarter of 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription